ERAS Erasca, Inc.
Executive Summary
17 institutions accumulated $24.5M in Erasca (ERAS) during 2024-Q3 (net +$9.8M vs. Q2), led by Citadel, Dimensional Fund Advisors, and Schwab. Six sellers exited or trimmed $21.2M, with Balyasny fully exiting a $10.2M position. The heavy active-manager buying alongside large quants signals conviction in Erasca's pipeline catalysts ahead of multiple near-term clinical readouts.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$11.7M
▲ Buyers (17)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Citadel | ADD | +31% | $11.8M | $4.0M |
| Dimensional Fund Advisors | DOUBLED | +141.6% | $3.3M | $2.1M |
| Schwab | ADD | +29.3% | $4.7M | $1.6M |
▼ Sellers (6)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Balyasny Asset Management | EXIT | -100% | $10.2M | -$10.2M |
| Janus Henderson Group | TRIM | -49.7% | $19.3M | -$8.1M |
| Point72 | NEAR_EXIT | -93.9% | $2.4M | -$2.3M |
Actionable Insight
Watch for next pipeline catalyst readout (likely within 1-2 quarters). The active-manager accumulation pattern at these share prices suggests institutional conviction in upcoming clinical data. Monitor additional 13F filings at next quarter for follow-through buying.
Key Facts
- 17 buyers added $9.8M net vs. 6 sellers who reduced $21.2M; aggregate buyer holdings reached $24.5M
- Citadel added 1.02M shares (+31%), now holding $11.8M — the largest buyer position
- Balyasny fully exited a $10.2M position (4.32M shares)
- Janus Henderson trimmed $8.1M (49.7%), remaining at $11.2M — the largest seller
- Point72 near-exited a $2.4M position, reducing to $174K
- Dimensional Fund Advisors doubled (+142%) to 1.21M shares ($3.3M), Verition +650% to $463K
- Cluster dominated by active managers and quant funds, not passive rebalancing — higher conviction signal
Financial Impact
Institutional net buying of $9.8M in Q3 vs. $21.2M in selling, with aggregate buyer holdings of $24.5M — approximately 1-2% of float transacted
Risk Factors
- Early-stage biotech binary risk — pipeline failure would negate accumulation thesis
- 45-day filing lag; positions may have been unwound since quarter-end
- Janus Henderson and Balyasyn sell side offsets a portion of buying conviction
Market Snapshot
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-ERAS-2024-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
Institutional Cluster
| $14.03 awaiting T+5 | awaiting T+5 | — | — |
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $13.70 awaiting T+5 | awaiting T+5 | — | — |
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $13.13 awaiting T+5 | awaiting T+5 | — | — |
|
May 11, 2026
4w ago
|
Press Release
| $10.44 $10.27 | ▼ −1.63% | ▼ −1.54% | — |
|
Apr 28, 2026
6w ago
|
DEFA14A
| $9.11 $9.99 | ▲ +9.66% | ▲ +6.55% | — |
|
Apr 27, 2026
6w ago
|
8-K
| $9.90 $10.14 | ▲ +2.42% | ▲ +0.73% | — |
|
Apr 27, 2026
6w ago
|
Press Release
| $9.90 $10.14 | ▲ +2.42% | ▲ +0.73% | — |
|
Apr 27, 2026
6w ago
|
8-K
| $19.15 $10.14 | ▼ −47.05% | ▼ −47.45% | — |
|
Apr 21, 2026
7w ago
|
8-K
| $22.41 $9.90 | ▼ −55.82% | ▼ −56.91% | — |
|
Mar 12, 2026
13w ago
|
Press Release
| $13.62 $14.60 | ▲ +7.20% | ▲ +9.31% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access